We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Monday
May 18
17:00 - 18:00
Viktoria
Prostate cancer 2
Pervin Hurmuz, Turkey;
Zhuolin Yang, United Kingdom
Proffered Papers
Clinical
17:00 - 18:00
PERSIAN TRIAL (NCT03449719): a randomized phase II trial testing Apalutamide and SBRT for hormone-sensitive prostate cancer
Giulio Francolini, Italy
-1415
17:00 - 18:00
Acute Toxicity in the DESTINATION 1 Trial: A Prospective Prostate SBRT Dose De-escalation Feasibility Study
Sian Cooper, United Kingdom
-2713
17:00 - 18:00
Patient-Reported Outcomes from a Randomized Non-inferiority Trial of Hypofractionation via Extended vs. Accelerated Therapy (HEAT) for Prostate Cancer
David Lee, USA
-3329
17:00 - 18:00
Results of a Randomized Non-inferiority Trial of Hypofractionation via Extended versus Accelerated Therapy (HEAT) for Prostate Cancer
Matthew abramowitz, USA
-3280
17:00 - 18:00
Late Toxicity and Longitudinal Quality-of-Life after Pelvis-inclusive SBRT vs IMRT for High-Risk Prostate Cancer: The SRAM Randomized Phase II Trial
Darren MC Poon, China, Hong Kong Special Administrative Region
-1689
17:00 - 18:00
Prospective randomized controlled trial of hyaluronic acid spacer for hypofractionated prostate radiation therapy: 3-year results (NCT04189913)
Martin King, USA
-3623
17:00 - 18:00
Dosimetry results from a global randomized trial of iodinated perirectal spacing in prostate cancer patients treated with SBRT (NCT04905069)
Pierre Blanchard, France
-2390